Abstract
Previous studies proposed that CYP1A2 rs762551 polymorphism might be associated with risk of lung cancer by influencing the function of CYP1A2. However, previous studies on the association between CYP1A2 rs762551 polymorphism and risk of lung cancer reported inconsistent findings. We performed a meta-analysis of the published case–control studies to assess the association between CYP1A2 rs762551 polymorphism and risk of lung cancer. PubMed and Embase were searched to identify relevant studies on the association between CYP1A2 rs762551 polymorphism and risk of lung cancer, and seven studies with a total of 3,320 subjects were finally included into the meta-analysis. The pooled odds ratio (OR) and 95 % confidence interval (95%CI) was calculated to evaluate the association. Meta-analysis of total studies showed that CYP1A2 rs762551 polymorphism contributed to risk of lung cancer under all four genetic models (C versus A: OR = 1.26, 95%CI 1.13 to 1.40, P < 0.001; CC versus AA: OR = 1.61, 95%CI 1.28 to 2.04, P < 0.001; CC versus AA/AC: OR = 1.52, 95%CI 1.11 to 2.09, P = 0.009; CC/AC versus AA: OR = 1.28, 95%CI 1.10 to 1.48, P = 0.001). Subgroup analysis based on ethnicity further suggested that CYP1A2 rs762551 polymorphism was associated with risk of lung cancer in Caucasians. These results from the meta-analysis suggest that CYP1A2 rs762551 polymorphism contributes to risk of lung cancer.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.
Marshall AL, Christiani DC. Genetic susceptibility to lung cancer–light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.
Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.
Oyama T, Uramoto H, Kagawa N, Yoshimatsu T, Osaki T, Nakanishi R, et al. Cytochrome p450 in non-small cell lung cancer related to exogenous chemical metabolism. Front Biosci (Schol Ed). 2012;4:1539–46.
Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Lung cancer susceptibility: are we on our way to identifying a high-risk group? Future Oncol. 2007;3:617–27.
Tan XL, Spivack SD. Dietary chemoprevention strategies for induction of phase ii xenobiotic-metabolizing enzymes in lung carcinogenesis: a review. Lung Cancer. 2009;65:129–37.
Nebert DW, Dalton TP. The role of cytochrome p450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947–60.
Nishikawa A, Mori Y, Lee IS, Tanaka T, Hirose M. Cigarette smoking, metabolic activation and carcinogenesis. Curr Drug Metab. 2004;5:363–73.
Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the cyp1 enzymes in environmental toxicity and cancer. J Biol Chem. 2004;279:23847–50.
Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes p450 (cyp) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009;60:217–42.
Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007;28:1287–93.
Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S, et al. Nat2 and cyp1a2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev. 2007;8:103–8.
B'Chir F, Pavanello S, Knani J, Boughattas S, Arnaud MJ, Saguem S. Cyp1a2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci. 2009;84:779–84.
Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N, et al. Polymorphism in cytochrome p450 1a2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark. 2010;8:351–9.
Gervasini G, Ghotbi R, Aklillu E, San Jose C, Cabanillas A, Kishikawa J, et al. Haplotypes in the 5'-untranslated region of the cyp1a2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environ Mol Mutagen. 2013;54:124–32.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
Aldrich MC, Selvin S, Hansen HM, Barcellos LF, Wrensch MR, Sison JD, et al. Cyp1a1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res. 2009;69:2340–8.
Pavanello S, Fedeli U, Mastrangelo G, Rota F, Overvad K, Raaschou-Nielsen O, et al. Role of cyp1a2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet. 2012;205:278–84.
Zhao Y, Chen ZX, Rewuti A, Ma YS, Wang XF, Xia Q, et al. Quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer risk. PLoS One. 2013;8:e71481.
Tian Z, Li YL, Zhao L, Zhang CL. Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case–control studies. Gene. 2013;524:168–74.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.
An erratum to this article can be found online at http://dx.doi.org/10.1007/s13277-017-5487-6.
About this article
Cite this article
Ma, Z., Guo, W., Gong, T. et al. RETRACTED ARTICLE: CYP1A2 rs762551 polymorphism contributes to risk of lung cancer: A meta-analysis. Tumor Biol. 35, 2253–2257 (2014). https://doi.org/10.1007/s13277-013-1298-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1298-6